

19 Oct 2020 |

Quick Listen: Scrip's Five Must-Know Things

by **Ian Haydock**

Join us for a brief audio roundup of the major developments in the international biopharma industry over the past week, as covered by Scrip's global team.

Take a brief audio tour around Scrip's Five Must-Know Things, this time for the business week ended 16 October 2020.

In this edition we take a look at progress and setbacks with coronavirus vaccines, a major deal in liver disease, one company's plans in immunology, and prospects for the global oncology market.

[Click here to explore this interactive content online](#) ✎

These and other Informa Pharma Intelligence podcasts are available on SoundCloud and Apple Podcasts.

Stories mentioned in this episode:

(Also see "[Pfizer's First COVID-19 Vaccine Results Might Be Just Days Away - But Patience Could Pay Off](#)" - Scrip, 14 Oct, 2020.)

(Also see "[J&J Says It's Wait And See On COVID-19 Vaccine Delay, Outlines Rosier Outlook for 2021](#)" - Scrip, 13 Oct, 2020.)

(Also see "[\\$1bn Deal Boosts Takeda, Arrowhead's Liver Disease And RNAi Ambitions](#)" - Scrip, 9 Oct, 2020.)

(Also see "[*BMS Sees Zeposia As Safer Oral Option In Ulcerative Colitis*](#)" - Scrip, 12 Oct, 2020.)

(Also see "[*R&D Trends Driving Broad Change In Surging Oncology Sector*](#)" - Scrip, 9 Oct, 2020.)